Description
Disclosures:
Nicholas Short: Astellas - Research Funding; Amgen - Honoraria; AstraZeneca - Consultancy; Takeda Oncology - Honoraria; Takeda Oncology - Consultancy; Takeda Oncology - Research Funding; Off Label Use - Yes.; Paper Off-Labe Use Disclosures -Blinatumomab - frontline therapy for ALL
Nicholas Short: Astellas - Research Funding; Amgen - Honoraria; AstraZeneca - Consultancy; Takeda Oncology - Honoraria; Takeda Oncology - Consultancy; Takeda Oncology - Research Funding; Off Label Use - Yes.; Paper Off-Labe Use Disclosures -Blinatumomab - frontline therapy for ALL
Jeffrey Rubnitz: AbbVie Inc. - Research Funding; Off Label Use - Yes.; Paper Off-Labe Use Disclosures -Yes, venetoclax is a BCL-2 inhibitor that is FDA approved for some indications. Venetoclax for treatment of acute lymphoblastic leukemia is not an approved indication.
Line Lynggaard: Nothing to Disclose; Off Label Use - No.
Liora Schultz: Nothing to Disclose; Off Label Use - No.
Andrej Lissat: Nothing to Disclose; Off Label Use - No.